<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 65-year-old female with <z:hpo ids='HP_0004820'>acute myelomonocytic leukemia</z:hpo> (AMMoL) developed from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), successfully treated with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> ocfosfate (SPAC) is reported </plain></SENT>
<SENT sid="1" pm="."><plain>Ubenimex, <z:chebi fb="0" ids="17823">calcitriol</z:chebi> and <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> had a minor effect on her <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Since she had severe <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> on developing <z:hpo ids='HP_0001909'>leukemia</z:hpo>, she was treated with oral administration of SPAC, a <z:chebi fb="0" ids="17562">cytidine</z:chebi> deaminase resistant derivative of Ara-C </plain></SENT>
<SENT sid="3" pm="."><plain>After the second course of SPAC (200 mg/day, for 14-28 days), marked erythroid bursts were found and she entered complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>The samplings of SPAC and its metabolites of SPAC were investigated in 2 cases including this case, but there seemed to be no relation between their content and effects </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, especially in cases developed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, SPAC might be useful because it can be given orally even in an outpatient </plain></SENT>
</text></document>